Abstract
Hepatitis B virus (HBV) is a significant global pathogen and efficient cure for HBV patients is still a challenging goal. We previously reported that acidic mucopolysaccharide from stichopus japonicus selenka (SJAMP) could inhibit HBsAg and HBeAg expression in vitro. However, the potential anti-HBV effects of SJAMP in vivo have not yet been explored. In this study, we show that SJAMP exhibits potent anti-HBV activity in HBV transgenic mice in a dose-dependent manner. Specifically, sixty HBV transgenic male BALB/c mice were randomly selected to receive the treatment of PBS, low dose SJAMP (30 mg kg−1), middle dose SJAMP (40 mg kg−1), high dose SJAMP (50 mg kg−1) and IFN (45 IU kg−1) for 30 d. SJAMP treatment suppressed serum HBV-DNA, and liver HBsAg and HBcAg levels in HBV-transgenic mice. The present study highlights the potential application of SJAMP in HBV therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 719-725 |
| Number of pages | 7 |
| Journal | Journal of Ocean University of China |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Aug 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Stichopus japonicus acid mucopolysaccharide
- antiviral
- hepatitis B virus
- transgenic mice
Fingerprint
Dive into the research topics of 'Antiviral effects of Stichopus japonicus acid mucopolysaccharide on hepatitis B virus transgenic mice'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver